ABSTRACT ADAM12, consisting of a membrane-bound (ADAM12L) and a secreted (ADAM12S) form, is expressed exclusively in regenerating and developing tissue as well as in certain cancer types. Strong ADAM12 expression levels have been noticed in the human placenta, and deregulated ADAM12S levels were associated with various pregnancy-related disorders including pre-eclampsia and intrauterine growth restriction. However, the role of ADAM12 in trophoblast motility has not been investigated so far. Hence, the present study aimed to investigate the specific function of the protease by using different primary trophoblast cell models. Immunofluorescence and Western blot analyses of first trimester placental tissue and differentiating primary first trimester cytotrophoblasts (CTBs) indicated strong upregulation of both of the ADAM12 isoforms during extravillous trophoblast differentiation. Functional assays involving short interfering RNA (siRNA)-mediated knockdown studies in primary CTBs and first trimester explant cultures revealed a significant repression of trophoblast motility upon partial loss of ADAM12. Conversely, isoform-specific overexpression in the ADAM12-negative trophoblast cell line SGHPL-5 enhanced the invasive capacity of these cells. We further confirmed proteolytic activity of trophoblast-derived ADAM12S by demonstrating its potential to degrade insulin-like growth factor-binding protein 3. Finally, we suggest that ADAM12S exerts its promigratory function in trophoblasts by inducing integrin beta 1-mediated cellular spreading.
INTRODUCTION
Extravillous trophoblast (EVT)-mediated invasion of the maternal decidua is one of the key events during early pregnancy, whereby trophoblasts, in concert with tissueresident cells such as uterine natural killer cells or deciduous stromal cells induce pivotal changes in the uteroplacental unit. These changes include maternal allorecognition of the fetus and placenta as well as regulation of the fetal blood supply by remodeling the uterine vasculature [1, 2] . EVT formation is characterized by a multistep differentiation process initiated by the development of proximal proliferative cell column trophoblasts (CCTs), which differentiate into noncycling invasive EVTs [3] . The latter acquires a highly motile phenotype in order to migrate along the basal membrane of spiral arteries or to invade maternal compartments, including decidual and myometrial tissues as well as the arterial vascular smooth muscle layer [4] . EVT motility is believed to depend on proteolytic activity facilitating degradation of steric barriers such as basement membranes or stromal extracellular matrices [5, 6] . Along this line of evidence, invasive EVTs have been reported to upregulate various proteases including matrix metalloproteinase 2 (MMP2) and -9 [7, 8] or urokinase plasminogen activator [9] . Another intriguing feature of proteases includes the proteolytic modification of cell-associated or soluble molecules such as growth factors, cytokines, and chemokines. Here, certain members of the ADAM family (a disintegrin and metalloproteinase) are well described for their ability to control proteolysis-dependent steps in signal transduction cascades or activation of bioactive factors [10] . For instance, ADAM-17 (also known as tumor necrosis factor [TNF]-converting enzyme) releases membrane-associated TNF-alpha and, similar to ADAM-10, cleaves Notch receptors (reviewed in ref. [10] ).
ADAM12 exists in 2 splice variants, the transmembrane version ADAM12L and the secreted ADAM12S form [11] . Both forms exhibit proteolytic activity via their identical extracellular regions, containing metalloproteinase, disintegrin, cysteine-rich and EGF-like domains [12] . The 2 forms differ in their C-terminal ends, consisting of a transmembrane and cytoplasmic tail domain in the membrane-bound version, which is replaced by a 33-amino-acid stretch in the secreted form [12] . Studies concentrating on either of the 2 ADAM12 variants have shown, for instance, that ADAM12L sheds membrane-associated factors such as pro-epidermal growth factor (EGF) [13] or delta-like 1 [14] , a critical ligand for Notch signaling. On the other hand, ADAM12S has been identified in the degradation of insulin-like growth factorbinding protein 3 (IGFBP3) and -5 [15] . Moreover, ADAM12 was shown to exert nonproteolytic functions by binding syndecan-4 and integrin (ITG) subunits such as b1, b3, a5, a6, and a7 via the disintegrin and cysteine-rich domains [16, 17] . Interestingly, previous studies report induction of the integrin subunit b1 (ITGB1) in EVTs [18, 19] . Similar to MMPs, ADAM12 is inhibited by tissue inhibitors of metalloproteinases (TIMPs), particularly by TIMP2 and TIMP3 [13, 15] . In contrast to adult tissues, ADAM12 is highly expressed in the human placenta [20] , and high serum levels of ADAM12S are found throughout the course of pregnancy [21] . Interestingly, reduced ADAM12S serum concentrations have been proposed to serve as prenatal makers for chromosomal abnormalities, including trisomy 13, 18, and 21 [21, 22] , as well as for pregnancies complicated by preeclampsia and intrauterine growth restriction (IUGR) [23, 24] . Despite these intriguing data suggesting a pivotal function for ADAM12 during pregnancy, no studies exist to unravel the particular role of ADAM12 in the human placenta.
MATERIALS AND METHODS

Placental Tissue Collection
Placental specimens (n ¼ 74) were obtained from elective pregnancy terminations of first trimester pregnancies (7th-12th wk of gestation [n ¼ 71]) and cesarean sections (37th-38th wk [n ¼ 3]). Tissues were collected with informed consent and utilization was approved by the Ethics Committee of the Medical University of Vienna.
Isolation and Cultivation of Human Primary First Trimester Cytotrophoblasts
Primary cytotrophoblasts (CTBs) were isolated by adapted enzymatic dispersion and Percoll (Sigma-Aldrich) gradient centrifugation, as described previously [25] . Briefly, placental villi were scraped with a scalpel blade and digested twice in 0.125% trypsin (Gibco, Life Technologies) and 12.5 mg/ml DNase I (Sigma-Aldrich) in 10% Mg 2þ /Ca 2þ -free Hanks balanced salt solution (Sigma-Aldrich) for 30 min at 378C. Cells were filtered through a 70-lm cell strainer (BD Biosciences) and poured into a 10%-70% Percoll gradient (Pharmacia). After centrifugation, cells between 35% and 50% of the Percoll layer were collected and incubated with erythrocyte lysis buffer (155 mM NH 4 Cl, 10 mM KHCO 3 , 0.1 mM EDTA, pH 7.3) for 5 min at room temperature. Placental fibroblasts were removed by incubation onto plastic dishes for 40 min. Cells were taken up in Dulbecco modified Eagle medium/ Ham F-12 (DMEM/Ham F-12) medium (PAA Laboratories), supplemented with 10% fetal calf serum (FCS; PAA Laboratories), 0.05 mg/ml gentamicin, and 0.5 lg/ml amphotericin B (Fungizone; both from Gibco), and plated on fibronectin-coated (20 lg/ml; BD Biosciences) 24-well plates at a density of 5 3 10 5 cells. Isolated CTBs were routinely stained against cytokeratin-7 and vimentin to confirm culture purity.
RNA Extraction and Real-Time PCR
RNA extraction and quantitative PCR (qPCR) were performed as described previously [26] . Briefly, total RNA was extracted with TriFast reagent (PeqLab) according to the manufacturer's instructions, and its quality was evaluated using the 2100 Bioanalyzer (Agilent Technologies). RNA was reverse-transcribed with RevertAid H Minus reverse transcriptase (Fermentas), and qPCR was performed using the Prism 5700 sequence detection system (Applied Biosystems). The probes ADAM12L (Hs 00185774_m1) and ADAM12S (Hs 00222216_m1) were obtained from Thermo Scientific. TATA-box binding protein was used as endogenous control (TaqMan; Life Technologies). Fold-changes in the amounts of RNA were calculated by the DDCt method.
Western Blot Analysis
Samples were lysed in Laemmli buffer, followed by boiling for 10 min. Proteins were separated by SDS-PAGE and blotted onto polyvinylidene fluoride membranes (GE Healthcare). After blocking in 5% non-fat dry milk in Tris-buffered saline containing 0.1% Tween 20 (TBST), membranes were incubated overnight at 48C with primary rabbit or mouse anti-human antibodies directed against ADAM12S (rabbit, rb116; 1:500 dilution, [27] ), ADAM12L (rabbit, 1:1000 dilution; catalog no. A2601; Sigma), GAPDH (rabbit, 1:1000 dilution; 14C10; Cell Signaling), IGFBP3 (mouse, clone 84728; catalog no. MAB305; 1:500 dilution; R&D Systems), and ITGA5 (mouse; 1:200 dilution; clone 10F6; catalog no. ab93943; Abcam) diluted in 5% bovine serum albumin BSA in Tris-buffered saline plus Tween 20 (TBST). In addition to ADAM12-negative adult tissue (skin samples), short interfering RNA (siRNA)-mediated knockdown of ADAM12 served as negative control for Western blot analysis. Transient overexpression of ADAM12 was used as the positive control, in particular for ADAM12S. Negative and positive controls for the ADAM12 signals obtained included analyses of ADAM12-negative adult tissue such as human skin lysates, siRNA-mediated knockdown, or transient overexpression of ADAM12, respectively. Membranes were washed with TBST and incubated with horseradish peroxidase-linked anti-mouse or anti-rabbit immunoglobulin G (IgG) secondary antibodies (1:50 000 dilution; GE Healthcare). Blots were developed using ECL Prime Western blotting detection reagent (GE Healthcare), and proteins were visualized using MultiImage III FC light cabinet and Alpha View version 3.1.1.0 software (Alpha Innotech).
Immunofluorescence Analysis
First trimester (7th-12th wk of gestation) and term trimester (37th-38th wk) placental tissues were embedded in paraffin and sectioned (3 lm) on a microtome. After deparafinization in xylol and rehydration in decreasing ethanol concentrations, sections were boiled in citrate buffer (pH 6; Thermo Scientific) and incubated with 0.05% fish skin gelatin (Sigma-Aldrich) for 30 min. Staining was performed overnight at 48C with primary rabbit or mouse anti-human antibodies directed against ADAM12 (rabbit, 1:1000 dilution; catalog no. 14139-1-AP; Proteintech Group), cytokeratin 7 (mouse, clone OV-TL; catalog no. M7018; 1:1000 dilution; Dako), ITGA5 (mouse; 1:200 dilution; clone 10F6; catalog no. ab93943), KI-67 (mouse; 1:100 dilution; catalog no. mab4190; Chemicon), and HLA-G1 (mouse; clone MEM-G/1; catalog no. LS-C179647; 1:100 dilution; LSBio). Irrelevant concentrationmatched primary antibodies were used as negative controls. After being washed, sections were incubated with goat anti-mouse or anti-rabbit IgG conjugated to Alexa Fluor 488 or 568 (2 lg/ml; Molecular Probes, Life Technologies) for 1 h at 378C and counterstained with DAPI (1 lg/ml; Roche). Sections were embedded in a slide mounting reagent (Fluoromount-G; SouthernBiotech) and analyzed by florescence microscopy (model BX50; Olympus).
siRNA Transfection of Primary CTBs and Placental Explants
Primary CTBs were cultivated in antibiotic-free growth medium and transfected with ADAM12 siRNA or nontargeting control (SMARTpool, ONTARGETplus; Thermo Scientific) using Lipofectamine RNAiMAX transfection reagent (Life Technologies) according to the manufacturer's instructions. First trimester placental explants (7th-9th wk of gestation) were dissected and cultivated on rat tail collagen-I (BD Biosciences). Subsequently, placental explants were transfected with respective siRNAs as described above. Ten explants were used per condition, and experiments were repeated 4 times. The area of outgrowth was digitally photographed after 48 h. To extract RNA or protein, after 48 h of cultivation, explants were incubated with RNAlater (Sigma-Aldrich) for 15 min, followed by removal of the placental anchoring villus and addition of TriFast reagent. RNA of 10 nontargeting control or ADAM12 siRNA-treated explants was pooled and homogenized using Precellys 24 homogenizer (Bertin Technologies). ADAM12 siRNA SMARTpools (product no. L-005118-00) contained a set of the following target sequences: CCAAUGCCGUUUCCAUAGA, CCAGAGGAAUGUAU GAAUC, UCAAGGCAACUAAGUAUGU, and CAAAUGCUCUGUAAGU CAG. Respective siRNA sets were used at a concentration of 40 nmol/L.
Motility Assay of Primary CTBs and SGHPL-5 Cells
Motility of primary CTBs was assessed 24 h after knockdown of ADAM12S by using 12-lm-pore transwell inserts (Merck Millipore) coated with 1 mg/ml fibronectin. When indicated, IGFBP3 (0.5 lg/ml or 2.5 lg/ml) was added (see Supplemental Fig. S1 ; Supplemental Data are available online at www.biolreprod.org). For ADAM12L-or ADAM12S-overexpressing SGHPL-5 cells, 8-lm-pore transwell inserts were coated with 0.15 mg/ml growth factor-reduced Matrigel (BD Biosciences). After 24 h, cells were fixed with 4% paraformaldehyde, followed by incubation with 0.1% Triton-X for 5 min and 0.05% fish skin gelatin for 30 min. Nonmigrated cells were removed using a cotton swab. Membranes were stained with anti-cytokeratin 7 and antivimentin antibodies and counterstained with 4 0 ,6-diamidino-2-phenylindole (DAPI). Finally, membranes were placed on glass slides and embedded in slide mounting medium. Images were acquired using fluorescence microscopy.
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Adhesion Assay of Primary Trophoblasts
An adhesion assay was performed as described previously [16] . Briefly, recombinant human (rhu) ADAM12 [15] or BSA was immobilized on uncoated or gelatin-coated wells for 1 h at 378C. Trophoblasts were seeded in equal numbers into the wells, followed by paraformaldehyde fixation after 1 h of attachment. Cells were stained with anti-cytokeratin 7 or anti-ITGB1 (1lg/ml [see below]) antibody, counterstained with DAPI, and embedded in slide mounting medium. Images were acquired with a fluorescence microscope. The number of adherent cells and the cellular area in the absence or presence of ADAM12S and/or a blocking antibody against ITGB1 (developed by C.H. Damsky and obtained from the Developmental Studies Hybridoma Bank, University of Iowa, Department of Biological Sciences, Iowa City, IA) [16] were determined using Cell^P software (Olympus).
IGFBP3 Cleavage Assay
To investigate the proteolytic properties of ADAM12S in trophoblast supernatants, a cleavage assay was performed. Briefly, 5 3 10 5 primary trophoblasts were transfected with siRNA oligonucleotides as described previously. Medium was replaced after 16 h, and supernatants were collected after another 48 h. Supernatants were 5-fold concentrated by centrifugation (3K15 unit; Sigma) and were incubated in the absence or presence of rhu IGFBP3 (5 lg/ml; R&D Systems) for 17 h at 378C, before being processed for Western blotting.
Transient Variant-Specific Overexpression of ADAM12 in SGHPL-5 Cells SGHPL-5 cells were cultivated in DMEM/Ham F-12 medium supplemented with 10% FCS and 0.05 mg/ml gentamicin. A total of 1 3 10 6 SGHPL-5 cells were transiently transfected with wild-type ADAM12S (ADAM12S wt ) [15] or truncated ADAM12L (ADAM12L Dtail GFP) [28] using Amaxa basic nucleofector kit for primary mammalian epithelial cells (Lonza) according to the manufacturer's instructions. Nucleofection was performed with a nucleofector device (Lonza) using W-001 software. After 48 h of cultivation, transfected cells were subjected to invasion assays.
Statistical Analyses
Statistical analyses were performed using an unpaired Student t-test. A t-test P value less than 0.05 was considered statistically significant. Gaussian distribution and equality of variances were examined with the KolmogorovSmirnov test and Levene test, respectively. In case of multiple comparisons, ANOVA and appropriate post hoc tests were performed.
RESULTS
ADAM12 Isoforms Are Strongly Upregulated in GrowthArrested Invasive EVTs
Analyses of the differential expression patterns of all human ADAM members in a published microarray-based gene expression study [29] of human fetal and adult tissues (retrieved from Gene Expression Omnibus [GEO], identifier GDS596) revealed abundant levels of ADAM12 mRNA in the human placenta (Supplemental Fig. S2 ). To elucidate the cellular origin of ADAM12 expression, we stained first trimester placental tissue sections using an antibody recognizing both isoforms of ADAM12. Well in line with our previously published data quantifying ADAM12 as one of the most upregulated genes during EVT differentiation [30] , we detected strong ADAM12 expression in invasive trophoblasts, which have invaded the decidua (Fig. 1A) . In detail, although KI67-positive proximal CCTs were mostly negative for ADAM12, the latter was found to be predominantly expressed in differentiated ITGA5-positive EVTs (Fig. 1A) . Additionally, we evaluated ADAM12 expression in isolated CTBs, which exhibit, when cultivated on extracellular matrices, gradual differentiation toward a growth-arrested invasive EVT phenotype [25, 26, 31] . Quantitative PCR (qPCR) revealed that ADAM12S and ADAM12L are strongly induced during EVT differentiation in vitro and absent from the trophoblast cell line SGHPL-5 (Fig. 1B) . Subsequent Western blot analyses using isoform-specific ADAM12 antibodies revealed that both ADAM12L expression in cellular lysates as well and ADAM12S secretion into the culture medium were gradually induced during EVT differentiation in vitro (Fig. 1C) . Differentiation of isolated trophoblasts was monitored by expression analyses of markers, which either disappeared during EVT differentiation, such as ITGA6 and Ki67, or were markers known to be induced in EVTs, including KIP2p57, ITGA1, ITGA5, and ITGA6, and T-cell transcription factor 4 (TCF4; also known as TCF7L2) at 24, 48, and 72 h of cultivation ( Fig. 1C and Supplemental Fig. S3 ). In agreement with published data, Western blotting of ADAM12L protein showed bands of 110 kD (pro form) and 90 kD (mature form), and detection of ADAM12S yielded a 68-kD signal [15, 28] . In addition, HLA-G1-positive EVTs migrating from first trimester placental explants strongly upregulated ADAM12 when detaching from the cell column (CC) (Fig. 1D) . ADAM12 expression in EVTs was sustained until term (Supplemental Fig. S4B ) and was generally absent from nontrophoblastic cells including cellular isolates derived from placental and decidual stroma and decidual whole-tissue extracts (Supplemental Fig.  S4A ). Moreover, we found pronounced ADAM12 staining in syncytiotrophoblasts (Supplemental Fig. S4B and data not shown), confirming existing literature [32] .
siRNA-Mediated Knockdown of ADAM12 Interferes with Trophoblast Motility
To study the role of ADAM12 in EVT function, we established an ADAM12 knockdown in primary trophoblast model system, using siRNAs targeting both isoforms of the protease. ADAM12 siRNA efficacy was tested in isolated primary CTBs as well as in placental explant cultures by qPCR and Western blot analyses showing a significant reduction of ADAM12L and -S mRNA and protein levels (Fig. 2, A and B) . Subsequent invasion assays revealed decreased motility rates of ADAM12-deficient primary CTBs by approximately 40% compared to control (Fig. 3A) . Knockdown of ADAM12 in placental explants provoked a decrease of EVT motility in these cultures (Fig. 3B) . Examination of the covered distance by disseminating migratory EVTs revealed a reduction of 60% compared to control (Fig. 3C) . Evaluation of apoptosis in siRNA-treated explant cultures revealed no signs for production of the apoptosis-associated cytokeratin 18 neoepitope in EVTs, suggesting that the reduced invasion rate upon ADAM12 knockdown was unlikely to be explained by elevated apoptosis rates in EVTs (Supplemental Fig. S5C) .
Furthermore, we analyzed whether reduced motility of ADAM12 siRNA-treated cultures could be due to changes in proliferation. However, knockdown of ADAM12 did not interfere with bromodeoxyuridine incorporation or KI67 positivity of 24-and 48-h cultivated trophoblasts (Supplemental Fig. S5, A and B) .
Variant-Specific Overexpression of ADAM12 Enhances Motility of SGHPL-5 Cells
Although the trophoblast cell line SGHPL-5 shows expression of specific trophoblast marker proteins (e.g., KRT7) and shares functional properties with primary EVTs [33] , we found that these cells lack ADAM12 expression. Consequently, we overexpressed ADAM12 in SGHPL-5 cells using isotype-specific overexpression constructs harboring either full-length ADAM12S or truncated ADAM12L
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FIG. 1. ADAM12 expression during EVT differentiation. A)
Immunofluorescence double staining on paraformaldehyde-fixed first trimester placental tissue sections (11th wk) using antibodies against ADAM12, KRT7, KI67, and ITGA5. DAPI staining was performed to visualize cell nuclei. Boxed areas show digitally zoomed insets (i and ii). Bars ¼ 50 lm. B) Primary trophoblasts were seeded onto fibronectin-coated wells, and mRNA was isolated to study ADAM12 expression in a time-dependent manner by qPCR. Bars ¼ percentage of the mean 6 SD (n ¼ 4) of ADAM12L and -S mRNA expression levels relative to the value obtained after 24 h of cultivation (set to 100%). *P , 0.05. C) Western blot analysis of ADAM12 isoforms in differentiating primary CTBs at different cultivation periods. Cellular lysates (CL) and supernatants (SN) were analyzed using antibodies recognizing isoform-specific ADAM12 BIADASIEWICZ ET AL.
(ADAM12L DtailGFP ), the latter of which lacksi the cytoplasmic tail, thus facilitating expression at the cell membrane [28] . Indeed, fluorescence microscopy showed that truncated ADAM12L
DtailGFP localizes to the cell membrane of transfected SGHPL-5 cells (Supplemental Fig. S6 ). Subsequent Western blot analyses confirmed transient overexpression of the respective ADAM12 variants (Fig. 4A ). In agreement with our knockdown studies, overexpression of ADAM12S or ADAM12L
DtailGFP significantly induced migration of SGHPL-5 cells compared to cells transfected with the empty vector control pcDNA or pEGFP-N3, respectively.
ADAM12S Is Proteolytically Active When Secreted from EVTs
ADAM12S is known to proteolytically degrade IGFBP3 [15] . To test whether trophoblast-derived ADAM12S is proteolytically active in vitro, we investigated its potential to degrade rhu IGFBP3. CTB-conditioned medium induced processing of full-length IGFBP3 (41 kD), resulting in the generation of 2 detectable cleavage products with molecular weights corresponding to approximately 25 and 30 kD. Interestingly, supernatants from ADAM12-deficient trophoblast cultures showed decreased proteolysis of rhu IGFBP3 (Fig. 5A) , indicating that trophoblast-derived ADAM12S is functionally active in culture. Quantification of Western blots revealed a 2-fold reduction in IGFBP3 processing upon gene silencing of ADAM12 (Fig. 5B) . However, addition of IGFBP3 did not alter trophoblast motility when added to control or ADAM12 siRNA-treated primary CTBs, showing that ADAM12S-mediated IGFBP3 processing does not directly influence trophoblast motility (Supplemental Fig. S1 ).
ADAM12 Induces ITGB1-Dependent Spreading in Primary CTBs
It has been suggested that various cell types show enhanced attachment and/or spreading upon binding to the cysteine-rich domain of ADAM12, which is common to both isoforms [34] . To this end, we immobilized rhu ADAM12S, which is identical to the extracellular region of ADAM12L, on either uncoated or gelatin-coated culture dishes and studied adhesion and spreading of primary CTBs. Although rhu ADAM12S did not influence trophoblast adhesion (Fig. 6A) , we found that the particular ADAM12 isoform strongly induces trophoblast spreading (Fig. 6C) . Of note, because we observed greatly diminished trophoblast attachment to plastic (Fig. 6A) , we continued our research using gelatin-coated dishes. The extent of spreading was approximately 1.9-fold increased when trophoblasts were seeded on ADAM12S-coated gelatin. As already mentioned, ADAM12 has been shown to associate with various integrin subunits including EVT-associated ITGB1 [18, 19] . Immunofluorescence analyses confirmed expression of ITGB1 in cultivated, primary trophoblasts (Fig. 6B) . Finally, when primary trophoblasts were treated with a blocking antibody specific to ITGB1, ADAM12S-induced spreading was fully blocked (Fig. 6, C and D) . Treatment with ITGB1 antibody alone did not influence CTB spreading (Fig. 6C) .
DISCUSSION
Acquisition of a highly motile and invasive phenotype is central to EVT-mediated processes including interaction with maternal decidual cells, as well as plugging and remodeling of spiral arteries. Failures in these processes are associated with severe pregnancy-related disorders such as pre-eclampsia or IUGR [35, 36] . Interestingly, recent studies suggest that preeclampsia is accompanied by defects in trophoblast-associated protease function and/or expression pattern of MMP9 and   FIG. 2 . siRNA-mediated ADAM12 knockdown in primary trophoblasts and outgrowing placental explant cultures. A) qPCR measuring ADAM12L and -S expression levels in differentiating primary CTBs or EVTs of placental explants after treatment with ADAM12 siRNA. RNA extraction from outgrowing placental explant-derived EVTs was performed as described in Materials and Methods. Bars ¼ percentage of the mean (6SD) of 3 (placental explants) or 4 (differentiating CTBs) independent experiments relative to nontargeting (ntc) control siRNA, set to 100%. *P , 0.05. B) Western blot analyses of ADAM12 knockdown efficacy in differentiating primary CTBs or explant-derived EVTs. Cellular lysates (CL) and supernatants (SN), prepared 48 h post-transfection, were analyzed with antibodies against ADAM12L, -S, and GAPDH. 
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HTRA serine peptidase 1 [37, 38] . Due to the significant correlation of altered serum levels of ADAM12S with pregnancy pathologies and its placenta-specific expression pattern (see below), we hypothesized that the particular protease might affect trophoblast function. Here, our results suggest that ADAM12 is highly expressed in invasive trophoblasts and facilitates trophoblast motility at least partly via ITGB1-mediated cellular spreading. While it is suppressed by a Z-DNA-forming negative regulatory element in adult tissues, ADAM12 is markedly induced in the placenta and in certain cancer types [20, 39] . Based on a microarray study comparing gene expression profiles of noninvasive villous CTBs to EVTs, we identified the latter as a potential cellular source for ADAM12 in the human placenta [30] . Indeed, various expression analyses including qPCR, Western blotting, and immunofluorescence staining indicated high expression levels of ADAM12 in growth-arrested invasive EVTs, whereas nontrophoblastic cells did not show expression of the particular protease. Therefore, we conclude that invasive EVTs comprise, together with syncytiotrophoblasts, the only cell type in the uteroplacental unit that expresses ADAM12. These findings further imply that trophoblasts regulate peripheral ADAM12S levels during pregnancy. Consequently, reduced ADAM12S serum levels in pre-eclamptic and IUGR patients may be due to defects in EVT function.
On the other hand, it remains elusive whether syncytiotrophoblasts also secrete ADAM12S and therefore may represent another cellular source for serum ADAM12S during pregnancy. Although that is not the scope of this study, a particular role for ADAM12 in syncytiotrophoblast formation and/or function seems likely, as ADAM12L is involved in regulating the bioavailability of EGF [40] . Interestingly, EGF promotes syncytialization in vitro [41] , and its receptor, EGFR, is highly expressed on the placental syncytium [42] . Moreover, ADAM12L plays a role in fusion of myoblast into multinucleated myotubes, a process with a variety of similarities to syncytiotrophoblast formation [43, 44] .
As mentioned above, EVTs strongly induce ADAM12 expression upon invasion into the maternal decidua. qPCR and Western blot analyses indicated upregulation of both the membrane-associated ADAM12L and the secreted ADAM12S isoforms. First, we found that ADAM12 knockdown negatively affected invasion of first trimester primary CTBs. In contrast to its growth-promoting effects during cancer progression [45] , ADAM12 did not alter trophoblast proliferation. This observation is well in line with our immunofluorescence studies demonstrating that ADAM12 is absent from proliferative trophoblast subtypes. In addition, we observed enhanced motility rates in both ADAM12L and -S forms in overexpress- White rectangles indicate digitally zoomed areas, presented at the bottom right side of each picture. Bars ¼ 50 lm. AU ¼ arbitrary units; EVT ¼extravillous trophoblast; VC ¼ villous core. C) Placental explants were placed on collagen-I and cultivated with medium containing nontargeting (ntc) or ADAM12-specific siRNAs. Graph shows the means (n ¼ 4) of the distances covered by migratory EVTs, which disseminated from the CC, and compared to ntctreated placental explants (set to 100% 6 SD).
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ing SGHPL-5 cells, further strengthening our hypothesis that ADAM12 promotes trophoblast migration.
Interestingly, a study performed by Irwin et al. [46] suggests that trophoblasts secrete an IGFBP-3 cleaving enzyme with similarities to an ADAM-type protease. We therefore tested the proteolytic degradation of IGFBP3 when incubated with supernatants derived from control or ADAM12 siRNA-treated primary CTBs. Indeed, our studies indicated that ADAM12S cleaves the particular protein. This finding implies that ADAM12S-mediated cleavage of IGFPB3 may affect IGF bioactivity in the fetal-maternal interface and in the serum of pregnant women. Han et al. [47] demonstrated that invasive trophoblasts express IGFBP3 and IGF1 and À2, particularly the last [47] . Although not the scope of this study, the regulatory effect of ADAM12S-mediated IGFBP3 cleavage in the context of IGF-controlled trophoblast function certainly deserves further attention. Furthermore, it is interesting to note that another member of the IGFBP family, namely IGFBP1, was shown to alter trophoblast invasion independently of its inhibitory effect on IGF activity [48, 49] . However, rhu IGFBP3 had no effect on the motility rates of ADAM12-expressing or ADAM12-deficient cells, suggesting that AD-AM12-mediated processing of IGFBP3 does not directly influence trophoblast motility. Similarly, addition of rhu 
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IGFBP3 had no effect on the migratory capacity of EVTs in placental explant cultures (data not shown). In addition, trophoblast-derived ADAM12S is likely to coregulate IGFBP3 cleavage in the serum of pregnant women for several reasons. First, as discussed above, adult tissue does not express ADAM12, and thus, the placenta is likely to comprise the only source for serum ADAM12S during pregnancy. This assumption is further supported by the finding that IGFBP3 cleavage in the serum disappears postpartum [46] . Second, we found that ADAM12S-mediated proteolysis of IGFBP3 results in 2 degradation products, the dominant fragment being 30 kDa in size. Of note, recent data show that a proteolytic IGFBP3 fragment of similar size was found in the serum of pregnant women exhibiting low binding affinity to IGF1 [50] . Consequently, trophoblast-derived ADAM12S may be involved in controlling IGF activity during pregnancy by proteolytically targeting serum IGFBP3.
ADAM12 has been observed to support cellular adhesion and/or spreading by its cysteine-rich domain, which is located at the extracellular part of the particular protease [17] . In this context, it is noteworthy, that ADAM12-deficient EVTs failed to spread and migrate from the distal end of the trophoblast CC (Fig. 3 ). Consequently, we tested the effect of immobilized rhu ADAM12S containing the cysteine-rich domain on trophoblast adhesion and spreading. While trophoblast adhesion was not affected, we found that rhu ADAM12S markedly induced cellular spreading of trophoblasts. Recent studies suggest that ADAM12-mediated cellular adhesion and spreading depend on the activation of ITGB1 [16, 34] . Because ITGB1 expression is strongly upregulated during invasive EVT differentiation [51] , we tested whether antibody-mediated blockage of ITGB1 would neutralize ADAM12-triggered spreading of primary CTBs. Indeed, measurement of the cellular area clearly revealed that ADAM12-mediated trophoblast spreading depends on the activation of ITGB1. Upon attachment, an increase of the adhesive area has been positively correlated with the recruitment and activation of the integrins vinculin and talin [52] . Whether the interaction between ADAM12 and ) after 1 h of attachment on ADAM12S immobilized on gelatin (6SD). ITGB1-dependent spreading was studied by adding a blocking antibody specific to ITGB1 or an irrelevant IgG-matched control antibody. D) Representative pictures of control-treated or ITGB1 AB-treated adherent KRT7-positve trophoblasts on gelatin in the presence of rhu ADAM12S or BSA. Digitally zoomed areas (i) are indicated by a white rectangle. BSA coating was used as a negative control. Bars ¼ 80 lm (original magnification) and 800 lm (digitally zoomed insets). *P , 0.05. AU ¼ arbitrary units; n.s. ¼ not significant.
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ITGB1 leads to activation of trophoblast-specific formation of lamellipodia and dynamic adhesive tractile structures, including integrin-mediated activation of focal adhesion kinase, vinculin, paxilin, and stress fibers [53, 54] , requires further investigation. Together, these data support a model in which binding of the extracellular domain of ADAM12 leads to integrin-dependent spreading of trophoblasts. This interaction may take place either in trans or in cis because the cysteinerich domain is common to both ADAM12 isoforms [16, 34] .
Finally, overexpression of the ADAM12L and -S forms enhances the migratory capacity of SGHPL-5 cells, which indicates that, apart from soluble ADAM12, the membraneanchored isoform also regulates trophoblast motility. Interestingly, ADAM12L activates EGF, a well known pro-migratory factor in trophoblast cell lines [55, 56] . However, there is strong evidence that trophoblast-associated EGFR expression is restricted to villous CTBs and proliferative, proximal CCTs suggesting that the particular growth factor is involved in trophoblast proliferation rather than motility [3, 31, 42, 57] . On the other hand, recent data indicate a prominent role for membrane-bound proteases in pericellular proteolysis. In particular, MT-MMP1 was seen to facilitate cellular invasion of various extracellular matrices [58] . In this context, it is interesting to note that ADAM12L-mediated activation of MT-MMP1 leads to enhanced tumor progression and gelatin degradation [59] . Finally, a recent study classified ADAM12 as an epithelium-to-mesenchyme transition (EMT)-induced gene. This finding may point to a similar regulation during EVT differentiation as these cells display typical EMT characteristics such as induction of Wnt signaling [60] , certain integrins [51] , or loss of E-cadherin [61] .
In summary, our data add novel mechanistic insights into protease activity controlling EVT motility. First, we showed that placental ADAM12 expression during the first trimester and at term is restricted to syncytiotrophoblasts and EVTs, which implies that pregnancy-specific upregulation of serum ADAM12S is regulated by trophoblasts. This further suggests that reduced ADAM12S levels during various pregnancy pathologies may be due to trophoblast dysfunction or altered trophoblast subtype distribution. Second, we demonstrated that ADAM12 promotes trophoblast motility, and in addition, we provide evidence for ADAM12S-mediated IGFBP3 cleavage during pregnancy. Finally, we suggest that ADAM12 promotes trophoblast spreading via EVT-specific activation of ITGB1.
